Mimedx (MDXG) Income from Continuing Operations (2011 - 2026)
Mimedx recorded quarterly Income from Continuing Operations of 10860000.0 in Q1 2026, down 171.49% quarter-over-quarter from 15191000.0 in Q4 2025, and down 254.63% year-over-year from 7023000.0 in Q1 2025.
Mimedx's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 10860000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 254.63% year-over-year to 10860000.0; the TTM figure through Mar 2026 stood at 30697000.0 (down 23.18% YoY), while the FY2025 annual figure was 48578000.0, up 15.67% from the prior year.
- Income from Continuing Operations came in at 10860000.0 for Q1 2026 at Mimedx, down from 15191000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 51288000.0 in Q4 2023 to a low of 10868000.0 in Q2 2022.
- A 5-year average of 7482588.24 and a median of 8842000.0 in 2023 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 4839.7% in 2022 and fell as far as 510.91% in 2022.
- Mimedx's Income from Continuing Operations stood at 9830000.0 in 2022, then soared by 421.75% to 51288000.0 in 2023, then plunged by 85.5% to 7438000.0 in 2024, then soared by 104.24% to 15191000.0 in 2025, then tumbled by 171.49% to 10860000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 10860000.0, 15191000.0, and 16748000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | -10.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.86 Mn |
| Dec 31, 2025 | 15.19 Mn |
| Sep 30, 2025 | 16.75 Mn |
| Jun 30, 2025 | 9.62 Mn |
| Mar 31, 2025 | 7.02 Mn |
| Dec 31, 2024 | 7.44 Mn |
| Sep 30, 2024 | 7.88 Mn |
| Jun 30, 2024 | 17.62 Mn |
| Mar 31, 2024 | 9.06 Mn |
| Dec 31, 2023 | 51.29 Mn |
| Sep 30, 2023 | 8.84 Mn |
| Jun 30, 2023 | 9.25 Mn |
| Mar 31, 2023 | -1.94 Mn |
| Dec 31, 2022 | 9.83 Mn |
| Sep 30, 2022 | -8.43 Mn |
| Jun 30, 2022 | -10.87 Mn |
| Mar 31, 2022 | -10.49 Mn |
| Dec 31, 2021 | 199,000.00 |
| Sep 30, 2021 | -2.34 Mn |
| Jun 30, 2021 | -1.78 Mn |
| Mar 31, 2021 | -8.38 Mn |
| Dec 31, 2020 | -16.58 Mn |
| Sep 30, 2020 | -19.42 Mn |
| Jun 30, 2020 | -8.47 Mn |
| Mar 31, 2020 | -4.82 Mn |
| Dec 31, 2019 | -7.48 Mn |
| Sep 30, 2019 | 12.38 Mn |
| Jun 30, 2019 | -17.21 Mn |
| Mar 31, 2019 | -13.27 Mn |
| Dec 31, 2018 | -36.22 Mn |
| Sep 30, 2018 | -178,000.00 |
| Jun 30, 2018 | 1.80 Mn |
| Mar 31, 2018 | 4.62 Mn |
| Dec 31, 2017 | 9.37 Mn |
| Sep 30, 2017 | 13.57 Mn |
| Jun 30, 2017 | 6.08 Mn |
| Mar 31, 2017 | 5.76 Mn |
| Dec 31, 2016 | -6.10 Mn |
| Sep 30, 2016 | 3.32 Mn |
| Jun 30, 2016 | 1.98 Mn |
| Mar 31, 2016 | 1.20 Mn |
| Dec 31, 2015 | 13.38 Mn |
| Sep 30, 2015 | 6.55 Mn |
| Jun 30, 2015 | 5.43 Mn |
| Mar 31, 2015 | 4.09 Mn |
| Dec 31, 2014 | 3.83 Mn |
| Sep 30, 2014 | 3.70 Mn |
| Jun 30, 2014 | -390,000.00 |
| Mar 31, 2014 | -922,000.00 |
| Dec 31, 2013 | -1.43 Mn |
| Sep 30, 2013 | -307,118.00 |
| Jun 30, 2013 | -757,389.00 |
| Mar 31, 2013 | -1.62 Mn |
| Dec 31, 2012 | -1.61 Mn |
| Sep 30, 2012 | -4.22 Mn |
| Jun 30, 2012 | -744,069.00 |
| Mar 31, 2012 | -1.09 Mn |
| Dec 31, 2011 | -2.58 Mn |
| Sep 30, 2011 | -1.77 Mn |
| Jun 30, 2011 | -2.50 Mn |
| Mar 31, 2011 | -3.35 Mn |